NICE Recommends Nilotinib for Chronic Myeloid Leukemia - OncologySTAT
Links shared publicly online about this topic.
- 51total visits
NICE Recommends Nilotinib for Chronic Myeloid Leukemia - OncologySTAT
View full resource at oncologystat.com
Tags: Leukemia, Chronic Myelogenous Leukemia, News, Medical
Most Recently Shared on August 23, 2011 at 9:56 pm By:
Price cut makes NICE withdraw their negative 'cost effectiveness' appraisal of Nilotinib in 2nd line CML treatment in UK http://ow.ly/6aXXN
NICE Final Recommendation Of Tasigna (nilotinib) For Some Ph+ Chronic Myeloid Leukaemia Patients Welcomed, UK - QualityPoint Technologies
qualitypointtech.net — “The decision by the National Institute for Health and Clinical Excellence (NICE) to recommend Tasigna (nilotinib) in the treatment of imatinib-resistant and imatinib-intolerant Philadelphia Chromosome (Ph+) chronic myeloid leukaemia (CML) was welcomed by Novartis Oncology. Although Dasatinib and high dose imatinib were appraised in the same setting, neither is recommended, with final Guidance expected to be in October 2011...” View full resource at qualitypointtech.net
Most Recently Shared on August 22, 2011 at 1:00 am By:
NICE Final Recommendation Of Tasigna (nilotinib) For Some Ph+ Chronic Myeloid Leukaemia Patients Welcomed, UK: The... http://t.co/GtzrvSG
NICE Final Recommendation Of Tasigna (nilotinib) For Some Ph+ Chronic Myeloid Leukaemia Patients Welcomed, UK
medicalnewstoday.com — “The decision by the National Institute for Health and Clinical Excellence (NICE) to recommend Tasigna (nilotinib) in the treatment of imatinib-resistant and imatinib-intolerant Philadelphia Chromo” View full resource at medicalnewstoday.com
Most Recently Shared on August 21, 2011 at 7:05 am By:
NICE Final Recommendation Of Tasigna (nilotinib) For Some Ph+ Chronic Myeloid Leukaemia Patients Welcomed, UK http://mnt.to/3Z6b
Macmillan Responds To NICE's Decision On Cancer Drug Azacitidine
medicalnewstoday.com — “Responding to the decision by NICE to recommend Azacitidine as a treatment for myelodyplastic syndrome, chronic myelomonocytic leukaemia, and acute myeloid leukaemia, Mike Hobday, Head of Policy a” View full resource at medicalnewstoday.com
Most Recently Shared on February 18, 2011 at 4:06 pm By:
Macmillan Responds To NICE's Decision On Cancer Drug Azacitidine http://mnt.to/3RjD #lymphoma #leukemia
NICE Appraisal Of Dasatinib And Nilotinib For Chronic Myeloid Leukaemia
medicalnewstoday.com — “The National Institute for Health and Clinical Excellence (NICE) has updated its draft guidance on the use of dasatinib (Sprycel,made by Bristol Myers-Squibb) and nilotinib (Tasigna,made by Novart” View full resource at medicalnewstoday.com
Most Recently Shared on February 9, 2010 at 5:13 pm By:
NICE Appraisal Of Dasatinib And Nilotinib For Chronic Myeloid Leukaemia http://mnt.to/3xpG #lymphoma #leukemia
Advertisement
